Back

Discovery of a novel antibiotic class targeting the enolase of Acinetobacterbaumannii

Molina Panadero, I.; Moreno Rodriguez, A.; de la Cruz, M.; Sanchez, P.; Tomas Gallardo, L.; Samernate, T.; Sencanski, M.; Glisic, S.; Genilloud, O.; Nonejuie, P.; Perez Pulido, A. J.; Hmadcha, A.; Smani, Y.

2025-04-24 microbiology
10.1101/2025.04.23.650324 bioRxiv
Show abstract

High-throughput screening studies provide an additional approach to discovering repurposed drugs for antimicrobial treatments. In this work, we report the identification of ENOblock, an anticancer drug, as a novel antibiotic class. We computationally and experimentally validated that ENOblock synergizes with colistin, the last resort antibiotic, the colistin. Additionally, we identified enolase as the potential bacterial target for ENOblock. The in silico and in vitro antibacterial activity of ENOblock translated into potent in vivo efficacy in animal infection model. Collectively, the preclinical data support the selection of ENOblock as a promising candidate for antimicrobial development, with the potential to address the urgent threat of infections caused by Acinetobacter baumannii.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.